retatrutide phase 2 nejm 2023 obesity trial jastreboff SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants Triple hormone receptor agonist retatrutide

If you want to look tanned, there are safer ways to do it than sunbathing or using sunbeds

10.1016/j.bmcl.2021.128486 113 XiongH.WangC.WangZ.JiangZ.ZhouJ.YaoJ

GLP-/GIP dual agonist innovatively integrates the effects of two incretin into one molecule, which can simultaneously activate GLP-1R and GIPR

"Our goal remains the same: to maximize access to safe, FDA-approved medications through a frictionless virtual care experience that delivers long-term and sustainable weight loss and health benefits for our patients. LifeMDs shift from compounded GLP-1s to direct partnerships with leading pharmaceutical manufacturers is central to its long-term growth strategy, reinforcing its commitment to emerging regulatory and reimbursement frameworks and to meeting rising demand for authentic obesity and metabolic care medications

Boost skin glow with Glutathione and Vitamin C